Featured Research

from universities, journals, and other organizations

Benefit of PET in malignant melanoma is unclear

Date:
July 20, 2011
Source:
Institute for Quality and Efficiency in Health Care
Summary:
The relevance of positron emission tomography alone or in combination with computed tomography in patients with malignant melanoma cannot be currently assessed, as the studies presently available do not allow robust conclusions.

The relevance of positron emission tomography (PET) alone or in combination with computed tomography (CT) in patients with malignant melanoma cannot be currently assessed due to a lack of meaningful studies.

This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 20 July 2011.

Hidden metastases are often detected too late

Malignant melanoma ("black skin cancer") may follow very different courses. In most patients the tumour can be removed completely by minor surgery. However, on first diagnosis some patients already have hidden metastases that are often detected only at a later stage. Many health care experts hope that an examination with PET or PET/CT, alone or in combination with other methods, can help detect hidden metastases as early as the first diagnosis. In addition, they hope that in follow-up examinations, PET or PET/CT can detect tumour recurrence earlier. The information obtained should then enable doctors to provide better treatment recommendations for patients.

Benefit for patients is crucial

IQWiG therefore searched the international scientific literature for studies investigating the impact of PET or PET/CT on health aspects directly relevant to patients. For example, the test results could help treat patients with further useful therapies at an earlier stage, or the results could help spare patients unnecessary treatment. However, the search for such studies was unsuccessful, so that the question as to the benefit of PET or PET/CT remained unanswered.

Reliability not clear

In addition, IQWiG searched for studies in which the diagnostic accuracy of PET or PET/CT was compared to other test methods. This investigates the question as to how often a PET test produces wrong results. The test should on the one hand overlook metastases as rarely as possible, but on the other, should not raise unjustified suspicions. Although a total of 17 diagnosis accuracy studies were found, the diagnostic accuracy of PET or PET/CT varied greatly in these studies. A comparison of PET or PET/CT with other technologies (e.g. CT alone) was investigated in only 2 studies, so that no general conclusions can be drawn for this question either.

Studies of high methodological quality are therefore urgently needed to investigate the benefit of PET or PET/CT in patients with malignant melanoma.

An overview of the background, methods and further results of the final report is provided in the following executive summary.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Benefit of PET in malignant melanoma is unclear." ScienceDaily. ScienceDaily, 20 July 2011. <www.sciencedaily.com/releases/2011/07/110720121903.htm>.
Institute for Quality and Efficiency in Health Care. (2011, July 20). Benefit of PET in malignant melanoma is unclear. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/07/110720121903.htm
Institute for Quality and Efficiency in Health Care. "Benefit of PET in malignant melanoma is unclear." ScienceDaily. www.sciencedaily.com/releases/2011/07/110720121903.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins